Related Experiment Videos
Sepsis and septic shock
G Zanetti1, J D Baumgartner, M P Glauser
1Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne.
Abstract:
Focal infectious processes may produce a systemic syndrome whose description has been recently standardized by the definitions of sepsis, severe sepsis and septic shock. This classification should only be used as an adjunct to the microbiological and clinical diagnosis of a given infection. The incidence of sepsis and septic shock has been increasing over recent decades, but the ratio of gram-negative to gram-positive causative organisms has remained largely similar (most often between 1:1 and 3:2). Recent advances in understanding of the pathophysiology of sepsis and septic shock have made it possible to delineate more clearly the role of bacterial products such as lipopolysaccharide, exotoxins or cell wall fragments. These products are able either to directly trigger inflammatory pathways, or to stimulate target cells (such as monocytic cells, PMN or endothelial cells) to produce pro-inflammatory cytokines. Management of the infectious process itself with antibiotics, and with surgery if needed, is the cornerstone of the therapy of sepsis and septic shock. More recent approaches aim at inhibiting the bioactivity of bacterial or pro-inflammatory mediators. Up to now, however, none of these approaches has led to therapeutic modalities that can be applied routinely to patients.
Insights
Sepsis and septic shock are systemic infections with increasing incidence. Understanding their pathophysiology and bacterial triggers is key, but current therapies, including novel approaches, are not yet routinely applicable.
Area of Science:
- Infectious Diseases
- Critical Care Medicine
- Pathophysiology
Background:
- Focal infections can lead to systemic syndromes like sepsis, severe sepsis, and septic shock.
- The incidence of sepsis and septic shock has risen, with a stable ratio of gram-negative to gram-positive bacteria.
- Standardized definitions aid diagnosis but should complement clinical and microbiological assessments.
Purpose of the Study:
- To review the pathophysiology of sepsis and septic shock.
- To discuss current and emerging therapeutic strategies.
- To highlight the role of bacterial products in triggering inflammatory responses.
Main Methods:
- Literature review of sepsis pathophysiology and treatment.
- Analysis of trends in sepsis incidence and causative organisms.
- Discussion of molecular mechanisms involving bacterial products and host inflammatory responses.
Main Results:
- Bacterial products (lipopolysaccharide, exotoxins, cell wall fragments) directly trigger or stimulate cells to produce pro-inflammatory cytokines.
- Antibiotics and surgical intervention remain the cornerstone of sepsis management.
- Emerging therapies targeting inflammatory mediators have not yet yielded routine clinical applications.
Conclusions:
- Sepsis and septic shock result from complex inflammatory pathways initiated by infectious agents.
- While understanding has advanced, effective routine therapies beyond foundational treatments are still under development.
- Continued research into inhibiting inflammatory mediators is crucial for future sepsis management.